Letter to the Editor Regarding "Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis".

Saved in:
Bibliographic Details
Title: Letter to the Editor Regarding "Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis".
Authors: Rand K; Maths in Health B.V., Klimmen, The Netherlands., Gebauer K; Fremantle Dermatology, Fremantle, Australia., Binamer Y; King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia., Cho YT; National Taiwan University Hospital, Taipei, Taiwan., Papadimitropoulos M; Eli Lilly and Company, Indianapolis, IN, USA., Yang C; Eli Lilly and Company, Indianapolis, IN, USA., Agell H; Almirall S.A., Barcelona, Spain., Akmaz B; Almirall S.A., Barcelona, Spain., Seminario-Vidal L; Eli Lilly and Company, Indianapolis, IN, USA. seminario_vidal_lucia@lilly.com.
Source: Dermatology and therapy [Dermatol Ther (Heidelb)] 2026 Jun 26. Date of Electronic Publication: 2026 Jun 26.
Publication Type: Letter; Comment
Journal Info: Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb)
Database: MEDLINE Ultimate
Description
ISSN:2193-8210
DOI:10.1007/s13555-026-01796-w